Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
30 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Angion Biomedica Corp. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Angion Biomedica Corp. - Product Pipeline Review - 2014', provides an overview of the Angion Biomedica Corp.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Angion Biomedica Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Angion Biomedica Corp. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Angion Biomedica Corp.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Angion Biomedica Corp.'s pipeline products Reasons to buy - Evaluate Angion Biomedica Corp.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Angion Biomedica Corp. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Angion Biomedica Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Angion Biomedica Corp. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Angion Biomedica Corp. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Angion Biomedica Corp. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Angion Biomedica Corp. Snapshot 5 Angion Biomedica Corp. Overview 5 Key Information 5 Key Facts 5 Angion Biomedica Corp. - Research and Development Overview 6 Key Therapeutic Areas 6 Angion Biomedica Corp. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Angion Biomedica Corp. - Pipeline Products Glance 11 Angion Biomedica Corp. - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Angion Biomedica Corp. - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Discovery Products/Combination Treatment Modalities 13 Angion Biomedica Corp. - Drug Profiles 14 BB-3 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 ANG-3070 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 ANG-3279 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 ANG-3281 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 ANG-3298 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 ANG-3557 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 ANG-4011 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Angion Biomedica Corp. - Pipeline Analysis 22 Angion Biomedica Corp. - Pipeline Products by Target 22 Angion Biomedica Corp. - Pipeline Products by Route of Administration 23 Angion Biomedica Corp. - Pipeline Products by Molecule Type 24 Angion Biomedica Corp. - Pipeline Products by Mechanism of Action 25 Angion Biomedica Corp. - Recent Pipeline Updates 26 Angion Biomedica Corp. - Dormant Projects 27 Angion Biomedica Corp. - Locations And Subsidiaries 28 Head Office 28 Appendix 29 Methodology 29 Coverage 29 Secondary Research 29 Primary Research 29 Expert Panel Validation 29 Contact Us 30 Disclaimer 30
List of Tables Angion Biomedica Corp., Key Information 5 Angion Biomedica Corp., Key Facts 5 Angion Biomedica Corp. - Pipeline by Indication, 2014 8 Angion Biomedica Corp. - Pipeline by Stage of Development, 2014 9 Angion Biomedica Corp. - Monotherapy Products in Pipeline, 2014 10 Angion Biomedica Corp. - Phase II, 2014 11 Angion Biomedica Corp. - Preclinical, 2014 12 Angion Biomedica Corp. - Discovery, 2014 13 Angion Biomedica Corp. - Pipeline by Target, 2014 22 Angion Biomedica Corp. - Pipeline by Route of Administration, 2014 23 Angion Biomedica Corp. - Pipeline by Molecule Type, 2014 24 Angion Biomedica Corp. - Pipeline Products by Mechanism of Action, 2014 25 Angion Biomedica Corp. - Recent Pipeline Updates, 2014 26 Angion Biomedica Corp. - Dormant Developmental Projects,2014 27
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.